ClinicalTrials.gg
Not yet recruitingNCT06517797Updated Jun 18, 2025

One-Year Study of S1B-509 vs Placebo for Weight Loss

A Phase 2 interventional study of S1B-509 low dose and Placebo in Obesity, sponsored by S1 Biopharma, Inc.. Not yet recruiting. Open to participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by S1 Biopharma, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
All
01

Study summary

This is a study to test whether S1B-509 given orally daily helps people with overweight or obesity to lose more weight than with placebo over a year.

Read the detailed description

This trial is to determine proof of concept for S1B-509 vs. placebo and to define a suitable dose escalation scheme and range for S1B-509 regarding safety, tolerability, and efficacy. The treatments will be given along with dietary advice and food intake monitoring. Change in body weight and in measures relating to obesity and its complications such as diabetes will be measured from baseline to week 48. Safety will be determined from adverse event reports, vital signs, routine laboratory tests, and mental health screeners.

02

Conditions studied

  • Obesity

Keywords

  • S1B-509; diabetes
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 210 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

S1 Biopharma, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with obesity disease and inadequately controlled body weight with diet and/or exercise
  • (BMI) ≥ 27 kg/m2 with significant comorbidity, e.g., type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease
  • Waist circumference at umbilical level ≥ 85 cm for male, ≥ 90 cm for female
  • Visceral fat area ≥ 100 cm2
  • Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study.
  • Side effects from any continuing concomitant medications must be mild and stable or nil.
  • Females: not pregnant or lactating for six months; using medically reliable , i.e., diaphragm or (male or female) condom and spermicide, IUD, tubal sterilization, hormonal contraception (oral, vaginal, or implant), or (if the investigator finds the patient credibly monogamous) vasectomy of male partner.
  • Gives for and is willing to undergo all of the scheduled evaluations.
  • Prompt for screening and baseline visits, is cooperative, and takes reasonable directions without excessive explanations.

Exclusion criteria

Exclusion Criteria:

  1. Use of pharmacologically active weight-loss medications, glucagon-like peptide-1 (GLP-1) agonists or sodium-glucose co-transporter 2 (SGLT2) inhibitors, within 3 months of screening, or between screening and randomization.
  2. Use of alpha glucosidase inhibitors within 3 months of Visit 1, or between screening and randomization.
  3. Bariatric surgery
  4. Lack of compliance with lifestyle intervention (defined as weight gain during 4-week Screening/run-in or with study medication (defined as \< 80% study drug intake in more than one 4-week period
  5. History of ketoacidosis, lactic acidosis, or hyperosmolar coma, or any of these occurring between Visit 1 and 2/randomization
  6. Diabetics with levels over 10 percent or fasting glucose levels greater than or equal to 270 mg/dl.
  7. Symptomatic infection in the 4 weeks prior to screening or randomization.
  8. Gastro-intestinal (GI) disorders associated with chronic diarrhea.
  9. Congestive heart failure, (NYHA) class III or IV
  10. Body dysmorphic disorder or compulsive eating disorder
  11. Chronic conditions that may in the investigator's judgment be expected to be unstable and affect overall health are not allowed. Examples: gastrointestinal bleeding in prior 6 months, diabetes mellitus with HB A1C >8.9, asthma not well controlled with treatment once or twice daily, current Major Depressive Disorder or recurrence of MDD off treatment for at least 2 months, anxiety disorder severe enough to prevent employment, severe sleep apnea, history within the prior year of suicidality or drug abuse, history of active breast, cervical, uterine, ovarian or other systemic cancer within the prior 24 months.
  12. Requires , CYP 2B6, or CYP 2D6 strong inhibitor or inducer drugs
  13. Takes any sex hormone other than an approved hormonal
  14. Takes an antiepileptic/mood stabilizer, antipsychotic, antidepressant, anxiolytic, or hypnotic drug
  15. Drinks more than 7 alcoholic drinks per week (12-oz beer, 4-oz wine, 1 ½ oz liquor etc)
  16. Uses marijuana more than once a week
  17. History of seizures as an adult or use of antiepileptic medication
  18. Long syndrome (QTc \<=480 msec), other significant cardiovascular disease (hypertension controlled with one medication is acceptable)
  19. Moderate or severe dysfunction of the liver (any LFT >=3x ) or renal dysfunction (BUN > 30 or Cr >2.0)
  20. Uses sedating antihistamines or prescription sedatives daily
  21. History of blood clots or abnormal bleeding tendencies, including daily use of medications adversely affecting coagulation, e.g., NSAIDs, systemic , or >81 mg aspirin daily.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    S1B-509 (proprietary combination of trazodone and bupropion) low dose

    Simultaneous oral dosing once daily with two to four extended-release tablets or capsules of S1B-509, for 48 weeks

    Drug: S1B-509 low dose

  • Placebo comparator
    Placebo

    Simultaneous oral dosing once daily with two to four placebos, for 48 weeks

    Drug: Placebo

  • Experimental
    S1B-509 (proprietary combination of trazodone and bupropion) high dose

    twice the dose of "S1B-509 low dose"

    Drug: S1B-509 High Dose

Interventions

  • DrugS1B-509 low dose

    S1B-509 has multiple neurotransmitter activities

    Also known as: proprietary combination of trazodone and bupropion at low dose

  • DrugPlacebo

    matched pills to S1B-509

  • DrugS1B-509 High Dose

    S1B-509 has multiple neurotransmitter activities

    Also known as: proprietary combination of trazodone and bupropion at high dose

06

What researchers measure

Primary outcomes

  1. Per cent weight change

    100 (Weight at follow-up) - (weight at baseline)/(weight at baseline)

    Time frame: 48 weeks

  2. Proportion losing at least 5% body weight

    (number of subjects (no. ss) per group losing at least 5% body weight)/(total no. ss/group

    Time frame: 48 weeks

Secondary outcomes

  1. Waist circumference

    measured waist in inches or centimeters

    Time frame: 48 weeks

  2. Proportion losing 10%

    per cent of patients per group losing ten percent weight, a substantial amount

    Time frame: 48 weeks

  3. Proportion losing 15%

    per cent of patients per group losing a highly substantial amount of weight

    Time frame: 48 weeks

  4. Change in systolic blood pressure

    average gain in systolic blood pressure per group

    Time frame: 48 weeks

  5. Change in diastolic blood pressure

    average change in diastolic pressure per group

    Time frame: 48 weeks

  6. Change in Hemoglobin A1c

    change in glycosylated hemoglobin, a measure of diabetes; normal is less than 6.5%

    Time frame: 48 weeks

  7. Change in Columbia suicidality screener

    6 yes/no items, patient-rated screener on suicide ideation and behavior, "no" on each is best

    Time frame: 48 weeks

  8. Change in Personal Health Questionnaire, 9-item version

    depression screener. Sum of 9 self-rated items from 0 (best) to 3 (worst).

    Time frame: 48 weeks

  9. Adverse events

    Change in subjective (answer to "how have you felt" or objective findings

    Time frame: 4 weeks

  10. Change in Female Sexual Function Index, Female

    19-item self-rated scale on sexual response, sum of ratings from 0 or 1 (worst) to 5 (best)

    Time frame: 4 weeks

  11. Change in International Index of Erectile Function, 5-item version

    5-item self-rated scale on erectile function, sum of items rated from 1 (worst) to 5 (best)

    Time frame: 4 weeks

  12. Edmonton Obesity Staging System

    Single-item categorical rating from 0 (normal) to 4 (severe)

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jun 2027, 20 months later.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 20 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 24, 2024
StartEst.
Oct 15, 2025
Primary completionEst.
Jun 15, 2027
CompletionEst.
Dec 15, 2027
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06517797
Lead sponsor
S1 Biopharma, Inc.
Responsible party
Sponsor
First posted
Jul 24, 2024
Start date
Oct 15, 2025 (estimated)
Primary completion
Jun 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Jun 18, 2025

Study contacts

Anita Clayton, MD
Contact
AHC8V@hscmail.mcc.virginia
4342434649
Robert E Pyke, MD,PhD
Contact
robertepyke@gmail.com
2033992390
Nicolas E Sitchon, B.S.
study chair · S1 Biopharma, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion